Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of the American Academy of Dermatology|November 29, 2025
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trialAthanasios Tsianakas, Thierry Passeron, Nina Magnolo, et al.
JAAD International|December 2, 2024
Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study)Dagmar Wilsmann-Theis, Selina Patt, Andreas Pinter, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
The Journal of Dermatology|September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisNatasha Mesinkovska, Brett King, Xingqi Zhang, et al.
Dermatology and Therapy|May 17, 2026
Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful TrialNina Magnolo, Jennifer Soung, John Frew, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
Lancet (London, England)|July 27, 2024
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I Silverberg, Andreas Wollenberg, Adam Reich, et al.
The New England Journal of Medicine|October 5, 2022
Trial of Intravenous Immune Globulin in DermatomyositisRohit Aggarwal, Christina Charles-Schoeman, Joachim Schessl, et al.
Lancet (London, England)|September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trialsLinda Stein Gold, April W Armstrong, Robert Bissonnette, et al.
The British Journal of Dermatology|August 12, 2025
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3-peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Christoph Hudemann, Holger Garn, et al.
Pageof 4